source
- BeOne Medicines trims five cancer programs and an autoimmune Phase 2 candidateBeOne Medicines has significantly broadened its research portfolio, adding 18 new molecular entities slated for development in 2024 and 2025. Despite the expansion, the company announced it will d…
- Pfizer CEO Albert Bourla rules out any transformative merger plansOn the May 5, 2026 earnings call, Pfizer chief Albert Bourla was asked whether the company was considering a transformative merger in the near or medium term. Bourla answered that Pfizer has no pl…